SCOPUS 정보 검색 플랫폼

Drug Discovery Today: Therapeutic Strategies

Volumn 8, Issue 3-4, 2011, Pages 131-137

Repositioned drugs: Integrating intellectual property and regulatory strategies

(1) Smith, Richard B a

a Edwards Angell Palmer and Dodge LLP (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DEXAMETHASONE; DOXEPIN; DULOXETINE; FINASTERIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; NALTREXONE; PLERIXAFOR; SILDENAFIL; THALIDOMIDE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BIRTH DEFECT; DEPRESSION; DRUG CAPSULE; DRUG DEPENDENCE; DRUG FORMULATION; DRUG INDICATION; DRUG MANUFACTURE; DRUG REPOSITIONING; ERECTILE DYSFUNCTION; ERYTHEMA NODOSUM LEPROSUM; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSOMNIA; LEPROSY; MAJOR DEPRESSION; MALE TYPE ALOPECIA; MORNING SICKNESS; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NEOPLASM; OPIOID ADDICTION; PATENT; PROSTATE HYPERTROPHY; PULMONARY HYPERTENSION; SMOKING CESSATION; STRESS INCONTINENCE; SUSTAINED RELEASE FORMULATION; TABLET;

EID: 84859267174 PISSN: None EISSN: 17406773 Source Type: Journal
DOI: 10.1016/j.ddstr.2011.06.008 Document Type: Review

Times cited : (62)

References (10)

1
- 84862173513
- Hatch-Waxman Act' 2011 [Public Law 98-417]
- 'Hatch-Waxman Act' 2011 [Public Law 98-417]

2
- 84862200019
- FDCA §505(b)(2); 21 USC §355(b)(2)
- FDCA §505(b)(2); 21 USC §355(b)(2)

3
- 84862212970
- FDCA §505(j); 21 USC §355.(j)
- FDCA §505(j); 21 USC §355.(j)

4
- 84862173516
- FDCA §505(b)(2)(a)(iv); 21 USC §355(b)(2)(a)(iv)
- FDCA §505(b)(2)(a)(iv); 21 USC §355(b)(2)(a)(iv)

5
- 84862173515
- FDCA §505(j)(2)(A)(vii)(IV); 21 USC §355(j)(2)(A)(vii)(IV)
- FDCA §505(j)(2)(A)(vii)(IV); 21 USC §355(j)(2)(A)(vii)(IV)

6
- 84862212969
- CHI Drug Repositioning Summit, October 6-7, 2008, Boston, MA, USA
- Smith, R.B. (2008) Drug repositioning: selecting the right business model and partner. CHI Drug Repositioning Summit, October 6-7, 2008, Boston, MA, USA
- (2008) Drug Repositioning: Selecting the Right Business Model and Partner
- Smith, R.B.¹

7
- 84862176351
- Integrating intellectual property and regulatory strategies to protect repositioned drugs
- September 18-19, 2008, Philadelphia, PA, USA
- Smith, R.B. (2008) Integrating intellectual property and regulatory strategies to protect repositioned drugs. Marcus Evans Drug Repositioning and R&D Enhancement Conference, September 18-19, 2008, Philadelphia, PA, USA
- (2008) Marcus Evans Drug Repositioning and R&D Enhancement Conference
- Smith, R.B.¹

8
- 84864775143
- Pharma. Law Insight July/August
- Manso, P.J. and Sokol, A.L. (2007) Life cycle management of ageing pharmaceutical assets. Pharma. Law Insight July/August, 16-19
- (2007) Life Cycle Management of Ageing Pharmaceutical Assets , pp. 16-19
- Manso, P.J.¹ Sokol, A.L.²

9
- 84862173517
- Insight Pharma Reports July extract of contents
- Mucke, H.A.M. (2010) Drug repositioning: extracting added value from prior R&D investments. Insight Pharma Reports July extract of contents
- (2010) Drug Repositioning: Extracting Added Value from Prior R&D Investments
- Mucke, H.A.M.¹

10
- 84862200018
- Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. Food and Drug Administration
- Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. Food and Drug Administration, http://www.accessdata. fda.gov/scripts/cder/ob/default.cfm

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.